.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Citi
Federal Trade Commission
Chinese Patent Office
US Department of Justice
Moodys
AstraZeneca
Teva
Cipla

Generated: September 21, 2017

DrugPatentWatch Database Preview

Sunovion Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for SUNOVION PHARMS INC, and what generic alternatives to SUNOVION PHARMS INC drugs are available?

SUNOVION PHARMS INC has seven approved drugs.

There are twenty-eight US patents protecting SUNOVION PHARMS INC drugs on SUNOVION PHARMS INC drugs in the past three years.

There are four hundred and sixty-four patent family members on SUNOVION PHARMS INC drugs in forty-seven countries.

Summary for Applicant: Sunovion Pharms Inc

Patents:28
Tradenames:7
Ingredients:7
NDAs:7
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
UTIBRON
glycopyrrolate ; indacaterol maleate
POWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► SubscribeYY ► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-001Oct 28, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-002Oct 28, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms Inc
ZONEGRAN
zonisamide
CAPSULE;ORAL020789-002Aug 22, 2003ABRXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms Inc
SEEBRI
glycopyrrolate
POWDER;INHALATION207923-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Sunovion Pharms Inc
LATUDA
lurasidone hydrochloride
TABLET;ORAL200603-004Apr 26, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Sunovion Pharms Inc
ARCAPTA NEOHALER
indacaterol maleate
POWDER;INHALATION022383-001Jul 1, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sunovion Pharms Inc

Paragraph IV activity for SUNOVION PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
lurasidone hydrochloride
Tablets20 mg, 40 mg, 60 mg, 80 mg, and 120 mg
LATUDA
10/28/2014
eszopiclone
Tablets1 mg, 2 mg and 3 mg
LUNESTA
12/15/2008

Non-Orange Book Patents for Sunovion Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,182,791Formulations for use in inhaler devices► Subscribe
8,871,274Pharmaceutical formulations for dry powder inhalers► Subscribe
9,585,839Particles for use in a pharmaceutical composition► Subscribe
5,780,632 Imide derivatives and their production and use► Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
8,258,139Method of treatment for mental disorders► Subscribe
9,040,559BETA2-adrenoceptor agonists► Subscribe
8,932,635Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation► Subscribe
7,605,260Process for producing imide compound► Subscribe
8,436,017Beta-2-adrenoreceptor agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sunovion Pharms Inc Drugs

Country Document Number Estimated Expiration
BrazilPI0511073► Subscribe
Slovenia1183240► Subscribe
United Kingdom0124010► Subscribe
Australia2211502► Subscribe
Slovenia1719505► Subscribe
Peru02192001► Subscribe
European Patent Office2332915► Subscribe
Austria173468► Subscribe
European Patent Office1670438► Subscribe
South Korea100376603► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sunovion Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/047United Kingdom► SubscribePRODUCT NAME: ESLICARBAZEPINE ACETATE; REGISTERED: UK EU/1/09/514/001 20090421; UK EU/1/09/514/002 20090421; UK EU/1/09/514/003 20090421; UK EU/1/09/514/004 20090421; UK EU/1/09/514/005 20090421; UK EU/1/09/514/006 20090421; UK EU/1/09/514/019 20090421; UK EU/1/09/514/020 20090421; UK EU/1/09/514/013 20090421; UK EU/1/09/514/014 20090421; UK EU/1/09/514/015 20090421; UK EU/1/09/514/016 20090421; UK EU/1/09/514/017 20090421; UK EU/1/09/514/018 20090421; UK EU/1/09/514/007 20090421; UK EU/1/09/514/008 20090421; UK EU/1/09/514/009 20090421; UK EU/1/09/514/010 20090421; UK EU/1/09/514/011 20090421; UK EU/1/09/514/012 20090421
2014000092Germany► SubscribePRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321
C009/2010Ireland► SubscribeSPC009/2010: 20100813, EXPIRES: 20241129
2014000025Germany► SubscribePRODUCT NAME: GLYCOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON (KOMPONENTE 1) UND INDACATEROL ODER EIN DERIVAT HIERVON ODER EIN SALZ VON INDACATEROL ODER EINEM DERIVAT HIERVON (KOMPONENTE 2); REGISTRATION NO/DATE: EU/1/13/862 20130919
166Luxembourg► SubscribePRODUCT NAME: GLYCOPYRRONIUM OU UN DE SES SELS
00406Netherlands► SubscribePRODUCT NAME: ESLICARBAZEPINE, DESGEWENST IN; REGISTRATION NO/DATE: EU/1/09/514/001-020 20090421
00690Netherlands► SubscribePRODUCT NAME: LURASIDON, OPTIONEEL IN DE VORM VAN ZIJN VRIJE BASE OF FARMACEUTISCH ACCEPTABELE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/14/913 20140321
1267866/02Switzerland► SubscribeFORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
9Finland► Subscribe
2013 00015Denmark► SubscribePRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, HERUNDER GLYCOPYRRONIUMBROMID; REG. NO/DATE: EU/1/12/788/001-006 20121003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
QuintilesIMS
Boehringer Ingelheim
Merck
AstraZeneca
Citi
Farmers Insurance
Healthtrust
McKesson
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot